Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | PREP | P48147 | 3/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.32 |
| ▸ | FEN1 | P39748 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17318153 | 0.72 | CA12 (0.47) | CA12CA1CA9PREPALOX5AP | |
| SCHEMBL6763899 | 0.72 | PREP (0.53) | CA12CA1CA9PREPALOX5AP | |
| SCHEMBL20970325 | 0.71 | KCNH2 (0.42) | KCNH2LMNAAPEX1PMP22 | |
| SCHEMBL25627201 | 0.68 | CA12 (0.38) | CA12CA1CA9PREPALOX5AP | |
| SCHEMBL26907586 | 0.68 | PREP (0.36) | CA12CA1CA9PREP | |
| SCHEMBL875675 | 0.67 | — | — | |
| SCHEMBL23491348 | 0.67 | PREP (0.57) | CA12CA1CA9PREPALOX5AP | |
| SCHEMBL2368966 | 0.67 | PREP (0.45) | CA12CA1CA9PREP | |
| SCHEMBL20358470 | 0.67 | PREP (0.49) | CA12CA1CA9PREP | |
| SCHEMBL480781 | 0.67 | NOS2 (0.37) | KCNH2LMNAAPEX1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127903-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-12048747-B2 | Substituted piperidine Degronimers for Target Protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| EP-4402139-A1 | FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS | Bisichem Co., Ltd. (KR) | 2024-07-24 | — | — | EP | disclosed |
| CN-118284604-A | Fused heterocycles as RIPK1 inhibitors | 比西切姆有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20240083892-A1 | FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS | BISICHEM CO., LTD. (KR) | 2024-03-14 | — | — | US | disclosed |
| WO-2023043284-A1 | FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS | BISICHEM CO., LTD. (KR) | 2023-03-23 | — | — | WO | disclosed |
| US-20220313827-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| EP-3455219-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2017197051-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2006040522-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005118572-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-12-15 | — | — | WO | disclosed |
| US-6617347-B1 | Substituted pyrazoles are treatment of Type II diabetes and obesity. | ELI LILLY AND COMPANY | 2003-09-09 | — | — | US | disclosed |
| EP-1036064-A4 | SELECTIVE BETA 3-ADRENERGIC AGONISTS | LILLY CO ELI (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6232337-B1 | USEFUL IN THE TREATMENT OF TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY | 2001-05-15 | — | — | US | disclosed |
| EP-1036064-A1 | SELECTIVE BETA 3-ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2000-09-20 | — | — | EP | disclosed |
| US-6046227-A | USEFUL IN THE TREATMENT OF TYPE II DIABETES AND OBESITY; A SUBSTITUTED PYRAZINE COMPOUND | ELI LILLY AND COMPANY (US) | 2000-04-04 | — | — | US | disclosed |
| WO-1999029673-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1999-06-17 | — | — | WO | disclosed |
| WO-1999029672-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1999-06-17 | — | — | WO | disclosed |
| EP-0921120-A1 | Selective beta 3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1999-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083892-A1 | FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS | RIPK1, RIPK3, RIPK4 | KCNH2 4549/4885LMNA 1514/4885APEX1 1032/4885 |
| US-20250127903-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, NEDD4 | KCNH2 4244/4885LMNA 3153/4885APEX1 282/4885 |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | KCNH2 4727/4885LMNA 3084/4885APEX1 181/4885 |
| US-20220313827-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, NEDD4 | KCNH2 4244/4885LMNA 3153/4885APEX1 282/4885 |
| US-12048747-B2 | Substituted piperidine Degronimers for Target Protein degradation | GID4, RNF5, UBE3C | KCNH2 4405/4885LMNA 3292/4885APEX1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.